Current status and future prospects for the development of substance abuse vaccines

References

• United Nations Office on Drugs and Crime (UNODC). World Drug Report. 2016. Available from: http://www.unodc.org/wdr2016/
   Google Scholar
• National Survey on Drug Use and Health (NSDUH). United States department of health and human services. Substance Abuse and Mental Health Services Administration. Center for Behavioral Health Statistics and Quality; 2015. Available from: https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR1-2015/NSDUH-FFR1-2015/NSDUH-FFR1-2015.htm
   Google Scholar
• U.S. Department of Justice, Drug Enforcement Administration. National drug threat assessment summary. 2015. Available from: https://www.dea.gov/docs/2015%20NDTA%20Report.pdf
   Google Scholar
• Ohia-Nwoko O, Kosten TA, Haile CN. Animal models and the development of vaccines to treat substance use disorders. Int Rev Neurobiol. 2016;126:263–291.
   PubMed Web of Science ®Google Scholar
• Pravetoni M. Biologics to treat substance use disorders: current status and new directions. Hum Vaccin Immunother. 2016 Dec;12(12):3005–3019.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. The health consequences of smoking—50 years of progress: a report of the surgeon general. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
   Google Scholar
• Rigotti NA. Strategies to help a smoker who is struggling to quit. JAMA. 2012 Oct 17;308(15):1573–1580.
   PubMed Web of Science ®Google Scholar
• Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016 Jun 18;387(10037):2507–2520.
   PubMed Web of Science ®Google Scholar
• Hatsukami DK, Jorenby DE, Gonzales D, et al. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther. 2011 Mar;89(3):392–399.
   PubMed Web of Science ®Google Scholar
• Fahim RE, Kessler PD, Kalnik MW. Therapeutic vaccines against tobacco addiction. Expert Rev Vaccines. 2013 Mar;12(3):333–342.
   PubMed Web of Science ®Google Scholar
• Hoogsteder PH, Kotz D, van Spiegel PI, et al. Efficacy of the nicotine vaccine 3ʹ-AmNic-rEPA (NicVAX) co-administered with varenicline and counselling for smoking cessation: a randomized placebo-controlled trial. Addiction. 2014 Aug;109(8):1252–1259.
   PubMed Web of Science ®Google Scholar
• Esterlis I, Hannestad JO, Perkins E, et al. Effect of a nicotine vaccine on nicotine binding to β2*-nicotinic acetylcholine receptors in vivo in human tobacco smokers. Am J Psychiatry. 2013 Apr;170(4):399–407.
   PubMed Web of Science ®Google Scholar
• Havermans A, Vuurman EF, van den Hurk J, et al. Treatment with a nicotine vaccine does not lead to changes in brain activity during smoking cue exposure or a working memory task. Addiction. 2014 Aug;109(8):1260–1267.
   PubMed Web of Science ®Google Scholar
• Tonstad S, Heggen E, Giljam H, et al. Niccine®, a nicotine vaccine, for relapse prevention: a phase II, randomized, placebo-controlled, multicenter clinical trial. Nicotine Tob Res. 2013 Sep;15(9):1492–1501.
   PubMed Web of Science ®Google Scholar
• Hartmann-Boyce J, Cahill K, Hatsukami D, et al. Nicotine vaccines for smoking cessation. Cochrane Database Syst Rev. 2012 Aug;15(8):CD007072.
   Google Scholar
• Maurer P, Jennings GT, Willers J, et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol. 2005 Jul;35(7):2031–2040.
   PubMed Web of Science ®Google Scholar
• Cornuz J, Zwahlen S, Jungi WF, et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One. 2008 Jun 25;3(6):e2547.
   PubMed Web of Science ®Google Scholar
• Pentel PR, LeSage MG. New directions in nicotine vaccine design and use. Adv Pharmacol. 2014;69:553–580.
   PubMedGoogle Scholar
• Pryde DC, Jones LH, Gervais DP, et al. Selection of a novel anti-nicotine vaccine: influence of antigen design on antibody function in mice. PLoS One. 2013;8(10):e76557.
   PubMed Web of Science ®Google Scholar
• McCluskie MJ, Thorn J, Mehelic PR, et al. Molecular attributes of conjugate antigen influence function of antibodies induced by anti-nicotine vaccine in mice and non-human primates. Int Immunopharmacol. 2015 Apr;25(2):518–527.
   PubMed Web of Science ®Google Scholar
• Ilyinskii PO, Johnston LP. Nanoparticle-based nicotine vaccine. In: Montoya ID, editor. Biologics to treat substance use disorders: vaccines, monoclonal antibodies, and enzymes. Cham: Springer; 2016. p. 249–278.
   Google Scholar
• Desai RI, Bergman J. Effects of the nanoparticle-based vaccine, SEL-068, on nicotine discrimination in squirrel monkeys. Neuropsychopharmacology. 2015 Aug;40(9):2207–2216.
   PubMed Web of Science ®Google Scholar
• Zheng H, Hu Y, Huang W, et al. Negatively charged carbon nanohorn supported cationic liposome nanoparticles: a novel delivery vehicle for anti-nicotine vaccine. J Biomed Nanotechnol. 2015 Dec;11(12):2197–2210.
   PubMed Web of Science ®Google Scholar
• Miller KD, Roque R, Clegg CH. Novel anti-nicotine vaccine using a trimeric coiled-coil hapten carrier. PLoS One. 2014;9(12):e114366.
   PubMed Web of Science ®Google Scholar
• Rosenberg JB, De BP, Hicks MJ, et al. Suppression of nicotine-induced pathophysiology by an adenovirus hexon-based antinicotine vaccine. Hum Gene Ther. 2013 Jun;24(6):595–603.
   PubMed Web of Science ®Google Scholar
• de Villiers SH, Cornish KE, Troska AJ, et al. Increased efficacy of a trivalent nicotine vaccine compared to a dose-matched monovalent vaccine when formulated with alum. Vaccine. 2013 Dec 16;31(52):6185–6193.
   PubMed Web of Science ®Google Scholar
• Pravetoni M, Keyler DE, Pidaparthi RR, et al. Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities. Biochem Pharmacol. 2012 Feb 15;83(4):543–550.
   PubMed Web of Science ®Google Scholar
• Cornish KE, Harris AC, LeSage MG, et al. Combined active and passive immunization against nicotine: minimizing monoclonal antibody requirements using a target antibody concentration strategy. Int Immunopharmacol. 2011 Nov;11(11):1809–1815.
   PubMed Web of Science ®Google Scholar
• Center for Behavioral Health Statistics and Quality (CBHSQ). Treatment Episode Data Set (TEDS): 2003-2013. In National admissions to substance abuse treatment services. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2015. BHSIS Series S-75, HHS Publication No. (SMA) 15-4934.
   Google Scholar
• NIH-NIDA. Drug facts: drug related hospital emergency room visits. 2011. Available from: https://www.drugabuse.gov/publications/drugfacts/drug-related-hospital-emergency-room-visits.
   Google Scholar
• Kosten TR, Newton TF, De La Garza R, et al. Cocaine and methamphetamine dependence: advances in treatment. 1st ed. Washington (DC): American Psychiatric Publishing; 2011.
   Google Scholar
• Domingo CB, Shorter D, Kosten TR. Vaccines for treating cocaine use disorders. In: Montoya ID, editor. Biologics to treat substance use disorders: vaccines, monoclonal antibodies, and enzymes. Cham: Springer; 2016. p. 25–36.
   Google Scholar
• Kantak KM, Collins SL, Lipman EG, et al. Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology (Berl). 2000 Feb;148(3):251–262.
   PubMed Web of Science ®Google Scholar
• Kantak KM, Collins SL, Bond J, et al. Time course of changes in cocaine self-administration behavior in rats during immunization with the cocaine vaccine IPC-1010. Psychopharmacology (Berl). 2001 Jan;153(3):334–340.
   PubMed Web of Science ®Google Scholar
• Kosten TR, Rosen M, Bond J, et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine. 2002 Jan 15;20(7–8):1196–1204.
   PubMed Web of Science ®Google Scholar
• Martell BA, Mitchell E, Poling J, et al. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry. 2005 Jul 15;58(2):158–164.
   PubMed Web of Science ®Google Scholar
• Martell BA, Orson FM, Poling J, et al. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch Gen Psychiatry. 2009 Oct;66(10):1116–1123.
   PubMed Web of Science ®Google Scholar
• Haney M, Gunderson EW, Jiang H, et al. Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol Psychiatry. 2010 Jan 1;67(1):59–65.
   PubMed Web of Science ®Google Scholar
• Deng SX, de Prada P, Landry DW. Anticocaine catalytic antibodies. J Immunol Methods. 2002 Nov 1;269(1–2):299–310.
   PubMed Web of Science ®Google Scholar
• Lindroth K, Mastache EF, Roos I, et al. Understanding thymus-independent antigen-induced reduction of thymus-dependent immune responses. Immunology. 2004 Jul;112(3):413–419.
   PubMed Web of Science ®Google Scholar
• Taylor JJ, Laudenbach M, Tucker AM, et al. Hapten-specific naïve B cells are biomarkers of vaccine efficacy against drugs of abuse. J Immunol Methods. 2014 Mar;405:74–86.
   PubMed Web of Science ®Google Scholar
• Laudenbach M, Tucker AM, Runyon SP, et al. The frequency of early-activated hapten-specific B cell subsets predicts the efficacy of vaccines for nicotine dependence. Vaccine. 2015 Nov 17;33(46):6332–6339.
   PubMed Web of Science ®Google Scholar
• Laudenbach M, Baruffaldi F, Vervacke JS, et al. The frequency of naive and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuse. J Immunol. 2015 Jun 15;194(12):5926–5936.
   PubMed Web of Science ®Google Scholar
• Kosten TR, Domingo CB, Shorter D, et al. Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial. Drug Alcohol Depend. 2014 Jul;1(140):42–47.
   Web of Science ®Google Scholar
• Koob G, Hicks MJ, Wee S, et al. Anti-cocaine vaccine based on coupling a cocaine analog to a disrupted adenovirus. CNS Neurol Disord Drug Targets. 2011 Dec;10(8):899–904.
   PubMed Web of Science ®Google Scholar
• Evans SM, Foltin RW, Hicks MJ, et al. Efficacy of an adenovirus-based anti-cocaine vaccine to reduce cocaine self-administration and reacqusition using a choice procedure in rhesus macaques. Pharmacol Biochem Behav. 2016 Nov– Dec;150-151:76–86.
   PubMed Web of Science ®Google Scholar
• Rudra JS, Ding Y, Neelakantan H, et al. Suppression of cocaine-evoked hyperactivity by self-adjuvanting and multivalent peptide nanofiber vaccines. ACS Chem Neurosci. 2016 May 18;7(5):546–552.
   PubMed Web of Science ®Google Scholar
• Lockner JW, Eubanks LM, Choi JL, et al. Flagellin as carrier and adjuvant in cocaine vaccine development. Mol Pharm. 2015 Feb 2;12(2):653–662.
   PubMed Web of Science ®Google Scholar
• Carroll ME, Zlebnik NE, Anker JJ, et al. Combined cocaine hydrolase gene transfer and anti-cocaine vaccine synergistically block cocaine-induced locomotion. PLoS One. 2012;7(8):e43536.
   PubMed Web of Science ®Google Scholar
• Woods JH, Zhan CG. Enzyme-based cocaine pharmacotherapies: current status and projections for the future. In: Montoya ID, editor. Biologics to treat substance use disorders: vaccines, monoclonal antibodies, and enzymes. Cham: Springer; 2016. p. 145–166.
   Google Scholar
• Brimijoin WS. Viral gene transfer of enzymes. In: Montoya ID, editor. Biologics to treat substance use disorders: vaccines, monoclonal antibodies, and enzymes. Cham: Springer; 2016. p. 167–185.
   Google Scholar
• Zheng F, Zhan CG. Cocaine hydrolases designed from butyrylcholinesterase. In: Montoya ID, editor. Biologics to treat substance use disorders: vaccines, monoclonal antibodies, and enzymes. Cham: Springer; 2016. p. 187–225.
   Google Scholar
• Crane EH. Highlights of the 2011 Drug Abuse Warning Network (DAWN) findings on drug-related emergency department visits. The CBHSQ Report: February 22, 2013. Rockville, MD: Center for Behavioral Statistics and Quality, Substance Abuse and Mental Health Services Administration.
   Google Scholar
• Stevens MW, Henry RL, Owens SM, et al. First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers. MAbs. 2014;6(6):1649–1656.
   PubMed Web of Science ®Google Scholar
• Owens SM. Monoclonal antibodies. In: Montoya ID, editor. Biologics to treat substance use disorders: vaccines, monoclonal antibodies, and enzymes. Cham: Springer; 2016. p. 107–108.
   Google Scholar
• Wetzel HN, Ball WJ, Norman AB. Anti-cocaine monoclonal antibodies. In: Montoya ID, editor. Biologics to treat substance use disorders: vaccines, monoclonal antibodies, and enzymes. Cham: Springer; 2016. p. 109–117.
   Google Scholar
• Hambuchen MD, Stevens MW, Gunnell MG, et al. Discovery and development of an anti-methamphetamine monoclonal antibody for use in treating methamphetamine abuse. In: Montoya ID, editor. Biologics to treat substance use disorders: vaccines, monoclonal antibodies, and enzymes. Cham: Springer; 2016. p. 119–142.
   Google Scholar
• Shen XY, Kosten TA, Lopez AY, et al. A vaccine against methamphetamine attenuates its behavioral effects in mice. Drug Alcohol Depend. 2013 Apr 1;129(1–2):41–48.
   PubMed Web of Science ®Google Scholar
• Haile CN, Kosten TA, Shen XY, et al. Altered methamphetamine place conditioning in mice vaccinated with a succinyl-methamphetamine-tetanus-toxoid vaccine. Am J Addict. 2015 Dec;24(8):748–755.
   PubMed Web of Science ®Google Scholar
• Kosten TR, Kosten TA. Vaccines for methamphetamine use disorder. In: Montoya ID, editor. Biologics to treat substance use disorders: vaccines, monoclonal antibodies, and enzymes. Cham: Springer; 2016. p. 65–74.
   Google Scholar
• Moreno AY, Mayorov AV, Janda KD. Impact of distinct chemical structures for the development of a methamphetamine vaccine. J Am Chem Soc. 2011 May 4;133(17):6587–6595.
   PubMed Web of Science ®Google Scholar
• Miller ML, Moreno AY, Aarde SM, et al. A methamphetamine vaccine attenuates methamphetamine-induced disruptions in thermoregulation and activity in rats. Biol Psychiatry. 2013 Apr 15;73(8):721–728.
   PubMed Web of Science ®Google Scholar
• Miller ML, Aarde SM, Moreno AY, et al. Effects of active anti-methamphetamine vaccination on intravenous self-administration in rats. Drug Alcohol Depend. 2015 Aug;1(153):29–36.
   Web of Science ®Google Scholar
• Collins KC, Schlosburg JE, Lockner JW, et al. Lipid tucaresol as an adjuvant for methamphetamine vaccine development. Chem Commun (Camb). 2014 Apr 21; 50(31):4079–4081.
   PubMed Web of Science ®Google Scholar
• CDC. Wide-ranging online data for epidemiologic research (WONDER). Atlanta (GA): CDC, National Center for Health Statistics; 2016. Available from http://wonder.cdc.gov
   Google Scholar
• Rudd RA, Seth P, David F, et al. Increases in drug and opioid-involved overdose deaths — united States, 2010–2015. MMWR Morb Mortal Wkly Rep. ePub: 16 December 2016. DOI:10.15585/mmwr.mm6550e1
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Vital signs: today’s heroin epidemic – more people at risk, multiple drugs abused. MMWR. 2015. Available from: https://www.cdc.gov/vitalsigns/pdf/2015-07-vitalsigns.pdf
   Google Scholar
• Compton WM, Jones CM, Baldwin GT. Relationship between nonmedical prescription-opioid use and heroin use. N Engl J Med. 2016 Jan 14;374(2):154–163.
   PubMed Web of Science ®Google Scholar
• Raleigh MD, Pentel PR. Vaccines for opioid addiction. In: Montoya ID, editor. Biologics to treat substance use disorders: vaccines, monoclonal antibodies, and enzymes. Cham: Springer; 2016. p. 37–63.
   Google Scholar
• Schlosburg JE, Vendruscolo LF, Bremer PT, et al. Dynamic vaccine blocks relapse to compulsive intake of heroin. Proc Natl Acad Sci USA. 2013 May 28;110(22):9036–9041.
   PubMed Web of Science ®Google Scholar
• Stowe GN, Vendruscolo LF, Edwards S, et al. A vaccine strategy that induces protective immunity against heroin. J Med Chem. 2011 Jul 28;54(14):5195–5204.
   PubMed Web of Science ®Google Scholar
• Matyas GR, Rice KC, Cheng K, et al. Facial recognition of heroin vaccine opiates: type 1 cross-reactivities of antibodies induced by hydrolytically stable haptenic surrogates of heroin, 6-acetylmorphine, and morphine. Vaccine. 2014 Mar 14;32(13):1473–1479.
   PubMed Web of Science ®Google Scholar
• Berkowitz B, Spector S. Evidence for active immunity to morphine in mice. Science. 1972 Dec 22;178(4067):1290–1292.
   PubMed Web of Science ®Google Scholar
• Bonese KF, Wainer BH, Fitch FW, et al. Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature. 1974 Dec 20;252(5485):708–710.
   PubMed Web of Science ®Google Scholar
• Ma LX, Zhou Q, Zheng HB, et al. [Preparation and characterization of anti-morphine vaccine antibody]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2006 May;22(3):368–370.
   PubMedGoogle Scholar
• Kosten TA, Shen XY, O’Malley PW, et al. A morphine conjugate vaccine attenuates the behavioral effects of morphine in rats. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Aug;1(45):223–229.
   Web of Science ®Google Scholar
• Li QQ, Luo YX, Sun CY, et al. A morphine/heroin vaccine with new hapten design attenuates behavioral effects in rats. J Neurochem. 2011 Dec;119(6):1271–1281.
   PubMed Web of Science ®Google Scholar
• Li QQ, Sun CY, Luo YX, et al. A conjugate vaccine attenuates morphine- and heroin-induced behavior in rats. Int J Neuropsychopharmacol. 2014 Dec 7;18(5). pii: pyu093. DOI:10.1093/ijnp/pyu093.
   Web of Science ®Google Scholar
• Anton B, Leff P. A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents. Vaccine. 2006 Apr 12;24(16):3232–3240.
   PubMed Web of Science ®Google Scholar
• Raleigh MD, Pravetoni M, Harris AC, et al. Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats. J Pharmacol Exp Ther. 2013 Feb;344(2):397–406.
   PubMed Web of Science ®Google Scholar
• Raleigh MD, Pentel PR, LeSage MG. Pharmacokinetic correlates of the effects of a heroin vaccine on heroin self-administration in rats. PLoS One. 2014;9(12):e115696.
   PubMed Web of Science ®Google Scholar
• Jones JM, Raleigh MD, Pentel PR, et al. Stability of heroin, 6-monoacetylmorphine, and morphine in biological samples and validation of an LC-MS assay for delayed analyses of pharmacokinetic samples in rats. J Pharm Biomed Anal. 2013 Feb 23;74:291–297.
   PubMed Web of Science ®Google Scholar
• Rook EJ, Huitema AD, van den Brink W, et al. Population pharmacokinetics of heroin and its major metabolites. Clin Pharmacokinet. 2006;45(4):401–417.
   PubMed Web of Science ®Google Scholar
• Inturrisi CE, Schultz M, Shin S, et al. Evidence from opiate binding studies that heroin acts through its metabolites. Life Sci. 1983;33(Suppl 1):773–776.
   PubMed Web of Science ®Google Scholar
• Bogen IL, Boix F, Nerem E, et al. A monoclonal antibody specific for 6-monoacetylmorphine reduces acute heroin effects in mice. J Pharmacol Exp Ther. 2014 Jun;349(3):568–576.
   PubMed Web of Science ®Google Scholar
• Reuter P. Can heroin maintenance help Baltimore? 2009. Available from: www.abell.org/sites/default/files/publications/cja_HeroinMaintenance_0209.pdf
   Google Scholar
• Haemmig RB, Tschacher W. Effects of high-dose heroin versus morphine in intravenous drug users: a randomised double-blind crossover study. J Psychoactive Drugs. 2001 Apr–Jun;33(2):105–110.
   PubMed Web of Science ®Google Scholar
• Rentsch KM, Kullak-Ublick GA, Reichel C, et al. Arterial and venous pharmacokinetics of intravenous heroin in subjects who are addicted to narcotics. Clin Pharmacol Ther. 2001 Sep;70(3):237–246.
   PubMed Web of Science ®Google Scholar
• Pravetoni M, Le Naour M, Tucker AM, et al. Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens. J Med Chem. 2013 Feb 14; 56(3):915–923.
   PubMed Web of Science ®Google Scholar
• Pravetoni M, Raleigh MD, Le Naour M, et al. Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats. Vaccine. 2012 Jun 29;30(31):4617–4624.
   PubMed Web of Science ®Google Scholar